Winter Is Coming For 2016 Biopharma Fundraising
This article was originally published in Scrip
As the Borg often stated in Star Trek's Next Generation, resistance (to a falling stock market, in this case) is futile. So, with the backdrop of a prolonged recent sell-off in pharmaceutical and biotechnology stocks that started in mid-July and which may have paused or temporarily stabilized at the time of writing, I thought that it would be instructive to explore where the sector could end up in 2016. Surprisingly, it is not all bad news.
You may also be interested in...
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?